Zhang J, Song X J, Hou H Q, Tan G J, Bian G Y, Li B, Chen L P, Wang L, Guo L
Departement of Neurology, the Second Hospital of Hebei Medical University, Shijiazhuang 050000, China.
Zhonghua Yi Xue Za Zhi. 2016 Jul 5;96(25):1987-90. doi: 10.3760/cma.j.issn.0376-2491.2016.25.006.
To assess the electrophysiological subtypes of Guillain-Barré syndrome (GBS) acute inflammatory demyelinating polyneuropathy (AIDP) and acute motor axonal neuropathy (AMAN), and long-term prognosis in northeastern China.
One hundred and eighteen patients with GBS were recruited between 2010 and 2012 and retrospectively reviewed.
According to electrodiagnostic criteria, patients were classified as AMAN (49, 46.7%) or AIDP (39, 37.1%), or were unclassified (17, 16.2%). Between the AMAN and AIDP groups, age, sex, and clinical disability did not differ significantly, but the AMAN patients more frequently had preceding gastroenteritis. By 4 weeks after onset, 24.5% of the AMAN patients (12) and 33.3% of the AIDP patients (13) had regained the ability to walk; by 1 year, 77.6% of the AMAN patients (38) and 79.5% of the AIDP patients (31) could walk. Recovery was generally favorable in both subtypes. Immunotherapy was effective in patients with either AIDP or AMAN, and glucocorticoids and immunoglobulin treatment could achieve similar effect.
AMAN and AIDP are the main subtypes of GBS in northeastern China. The prognosis of patients with AMAN is similar to that of patients with AIDP. Different immunotherapies have similar effect on long term prognosis.
评估中国东北地区吉兰-巴雷综合征(GBS)急性炎症性脱髓鞘性多发性神经病(AIDP)和急性运动轴索性神经病(AMAN)的电生理亚型及长期预后。
回顾性分析2010年至2012年间招募的118例GBS患者。
根据电诊断标准,患者分为AMAN组(49例,46.7%)、AIDP组(39例,37.1%)或未分类组(17例,16.2%)。AMAN组和AIDP组在年龄、性别及临床残疾程度方面无显著差异,但AMAN患者前驱性胃肠炎更为常见。发病后4周时,24.5%的AMAN患者(12例)和33.3%的AIDP患者(13例)恢复行走能力;1年后,77.6%的AMAN患者(38例)和79.5%的AIDP患者(31例)能够行走。两种亚型的恢复总体良好。免疫治疗对AIDP或AMAN患者均有效,糖皮质激素和免疫球蛋白治疗效果相似。
AMAN和AIDP是中国东北地区GBS的主要亚型。AMAN患者的预后与AIDP患者相似。不同的免疫治疗对长期预后有相似的效果。